569250-U

Discovery^® HS C18 (3 µm) HPLC Columns

L × I.D. 5 cm × 4.6 mm, HPLC Column

• Sinonimo/i: Discovery RP18 HPLC Column
• Codice UNSPSC: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Proprietà

• product name: Colonna HPLC Discovery^® HS C18, 3 μm particle size, L × I.D. 5 cm × 4.6 mm
• Materiali: stainless steel column
• agenzia: suitable for USP L1
• Nome Commerciale: Discovery^®
• Caratteristiche: endcapped
• Produttore/marchio commerciale: Discovery^®
• Confezionamento: 1 ea of
• Grado di funzionalizzazione: 20% Carbon loading
• Parametri: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• tecniche: HPLC: suitable; LC/MS: suitable
• Lungh. × D.I.: 5 cm × 4.6 mm
• Area superficiale: 300 m²/g
• Copertura della superficie: 3.2 μmol/m²
• Impurezze: <10 ppm metals
• Matrice: silica gel, high purity, spherical particle platform; fully porous particle
• Gruppo funzionale matrice: C18 (octadecyl) phase
• Dimensione particelle: 3 μm
• Dimensione pori: 120 Å
• operating pH range: 2-8
• applicazioni: food and beverages
• Tecnica di separazione: reversed phase

Descrizione

Applicazioni

• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This study developed a robust RP-HPLC method to determine molnupiravir in various nanoformulations, showcasing its potential application in permeability studies and ensuring drug stability (Reçber et al., 2022) (Reçber et al., 2022).


• Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This research presented an HPLC-UV method for analyzing terizidone in plasma, facilitating its use in pharmacokinetic studies of patients with drug-resistant tuberculosis (Mulubwa and Mugabo, 2018) (Mulubwa and Mugabo, 2018).


• Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: The study optimized an LC method for quantifying doxorubicin in plasma and urine, crucial for pharmacokinetic, biomedical, and drug monitoring therapy applications (Maliszewska et al., 2018) (Maliszewska et al., 2018).

Caratteristiche e vantaggi

• Stabile, a bassa perdita per applicazioni LC-MS
• Scalabile dalla colonna analitica alla preparatoria
• Molto stabile per garantire una eccellente riproducibilità da un ciclo all′altro e da un lotto all′altro
• Maggiore idrofobia per una migliore risoluzione degli analiti difficili

   

Prodotti consigliati

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Note legali

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany